Ang aming pangunahing kontribusyon ay ang patuloy na paglabas ng therapy ay nagsasama ng mga pakinabang ng chemotherapy at immunotherapy, at sa kauna-unahang pagkakataon, ang dalawa ay pinagsama at inilapat sa intratumoral therapy sa pamamagitan ng interbensyon. It integrates local and global treatment, and increases the concentration and time of drug action through sustained release of drugs within the tumor, which not only plays a local anticancer effect of chemotherapy drugs, but also takes into account the role of systemic immunotherapy, thus making up for the shortcomings of other therapies, providing new ideas and approaches for cancer treatment, especially for middle and advanced tumors, especially for reducing tumor recurrence and inhibiting tumor The transfer has very mahalagang halaga; Ang Umpic Therapy ay may kalamangan sa paggamit ng tumor bilang pinagmulan ng antigen at autologous na bakuna, na naaayon din sa kalakaran ng pag -unlad ng isinapersonal na gamot. At inilapat sa klinika, ang hapten na sinamahan ng mga gamot na chemotherapy para sa matagal na paglabas ng paggamot ng cancer sa pancreatic cancer pangunahing pokus, habang ang pag-uudyok ng malayong epekto, ang kakanyahan kung saan ay upang pukawin ang tugon ng immune, T-cell na may kaugnayan sa CD4, CD8, DC, T at NK cells, at B-cell na may kaugnayan na tumor autoantibodies: antibody sa P53, P16, CMYC, ZETA,, Survivin, p62, HCC1 and other oncogenes, this is the first time to find that T and B are involved in the immune response, and the clinical functions of the distal effect and this therapy was selected for "Clinical Operation Guidelines for Interventional Treatment of Advanced Pancreatic Cancer" (Trial) (7th edition) jointly formulated by the Chinese Anti-Cancer Association, the National Clinical Medical Research Center for Radiology and Therapy, and the National Ang Interventional Medicine Innovation Alliance ay nai-publish sa Journal of Clinical Radiology, dami 43, bilang 19, 2024, 1636-1648.